Cargando…
Bispecific Antibodies and Advances in Non–Gene Therapy Options in Hemophilia
Regular prophylaxis has markedly improved the treatment for patients with hemophilia A, especially after the introduction of highly purified factor VIII (FVIII) concentrates. However, frequent intravenous infusions and the development of FVIII inhibitors remain as unsolved difficulties. To overcome...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292667/ https://www.ncbi.nlm.nih.gov/pubmed/32548546 http://dx.doi.org/10.1002/rth2.12337 |